NSE filing, NSE: PANACEABIO. Summary written from the filing by ALFA Finder's alert engine.
Panacea Biotec Ltd: key numbers
- Share price
- ₹329.95
- Market cap
- ₹2,021 Cr
- Revenue (annual)
- ₹639.8 Cr
- Net profit (annual)
- ₹-5.37 Cr
- P/E (TTM)
- -283.8×Sector 46.5×
- Promoter holding
- 72.48%+0.00% QoQ
- FII holding
- 2.75%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Panacea Biotec Ltd
All →Panacea Biotec Annual General Meeting
Panacea Biotec held its 42nd Annual General Meeting on September 29, 2026, where members considered and adopted various financial and operational business items.
Panacea Biotec Legal & Regulatory
Panacea Biotec received two Income Tax demand orders totaling ₹4.32 Crore for alleged income misreporting. The company disputes the demand and plans to file an appeal.
- Value
- ₹4.32 Cr
Panacea Biotec Legal & Regulatory
Panacea Biotec received four income tax demand orders totaling ₹9.82 Crore for alleged misreporting. The company contests this as non-maintainable and plans to appeal.
- Value
- ₹9.82 Cr
Panacea Biotec Other Announcement
Panacea Biotec sent reminder letters to physical shareholders requesting PAN and KYC updates per SEBI circulars. No transaction or business event is involved.
Panacea Biotec Annual General Meeting
Panacea Biotec Limited issued the notice for its 42nd Annual General Meeting scheduled for September 29, 2026, via video conferencing. Shareholders can participate through remote e-voting.
Panacea Biotec Capital Structure Change
Nosheen Sheikh, an employee's immediate relative, sold 3,000 equity shares of Panacea Biotec Ltd for ₹12.29 Lakh in a market sale.
- Value
- ₹0.12 Cr
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.